Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

tovaxin

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Background: Tovaxin is an autologous T-cell immunotherapy under investigation for the treatment of MS. The product consists of in… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
Review
2011
Review
2011
  • V. Rivera
  • Expert opinion on biological therapy
  • 2011
  • Corpus ID: 8211681
Introduction: A potential therapeutic possibility for multiple sclerosis (MS) is provided by Tovaxin, a personalized autologous T… Expand
2009
2009
An open-label dose escalation study of T-cell vaccination in multiple sclerosis patients was conducted using attenuated myelin… Expand
Review
2008
Review
2008
Opexa Pharmaceuticals Inc is developing Tovaxin, a trivalent formulation of attenuated myelin-peptide-reactive T-cells, for the… Expand